Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $2
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price target from $3 to $2.
Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price target from $3 to $2.